Research ArticleOpen Access

The Use of Nephrotoxic Medicament in Family Medicine

Volume 3 - Issue 2

**Ibrahim Rudhani*¹, Ahmet Avdullahu¹, Naim Morina², Azem Spahiu³, Lirim Spahiu⁴ and Pajtesa Kryeziu⁴**

Author Information Open or Close
- ¹Internal Medicine Specialist - Nephrologist, Clinic for Neophrology and Hemodialysis UCCK, Kosovo
- ²Resident of Internal Medicine Clinic of Nephrology and Hemodialysis, UCCK Kosovo Hospital, Kosovo
- ³Specialist of family medicine, Family Medicine Center, Kosovo
- ⁴University of Pristina, Kosovo
*Corresponding author: Ibrahim Rudhani, Internal Medicine Specialist – Nephrologist, Clinic for Neophrology and Hemodialysis UCCK , Hospital Circle n.n. 10000 Pristina, Kosovo

Received: March 03, 2018; Published: March 27, 2018

DOI: 10.26717/BJSTR.2018.03.000887

Full Text PDF

To view the Full Article Peer-reviewed Article PDF

Abstract

The purpose of this paper is to investigate the cases in which the nephrotoxic medicaments analyzed in this paper have been prescribed and the expression of the nephrotoxic side effects to the patients.Prospective method was used for this work. The study included 5076 patients, which 1437 were treated with nephrotoxic medicament such as Diclofenac, Gentamicin, Brufen, Sulidamor, etc, during the period December 1, 2016 to May 31, 2017 at the Family Medicine Center in Rogane- Kamenicë. Out of 5076 patients in the period December 2016 to May 2017, 1438 patients were treated with nephrotoxic medicament analyzed in this paper, which 571 were male and 867 female. 34 had symptoms of kidney damage, and 3 of them exposed dialysis. This study shows that the nephrotoxic medicament analyzed in this paper were prescribed in primary care with a prevalence of 28%, predominating females by 60% compared to 40% in masculinity. From this study it emerges that these medicament had nephrotoxic effects to patients treated with a prevalence of 3.2%.

Keywords: Kidney; Nephrotoxic medicament; Dialysi